EU MDR Clinical Evaluation

Technical Documentation

Overview

For CE marking and throughout the device’s lifecycle, medical device manufacturers must demonstrate conformity with Regulation (EU) 2017/745 (MDR), notably the General Safety and Performance Requirements (GSPRs) set out in Annex I. A core part of meeting the GSPRs is the obligation to plan, conduct, document, and continuously update the clinical evaluation. The EU MDR clinical evaluation process builds upon the MEDDEV 2.7/1 rev. 4 guidance “Clinical evaluation: Guide for manufacturers and notified bodies” but introduces additional mandatory requirements including documented plans for the clinical evaluation and post market clinical follow-up. Further, manufacturers of devices, even those that have been on the market for many years, must establish and maintain an active Post-Market Surveillance (PMS) system to continuously collect and analyze post-market data, ensuring that clinical evaluations and risk management files are regularly updated with real-world evidence.

The table below provides a summary of the associated technical documents according to device risk classification; a common challenge is consistency and alignment across all MDR technical documentation, including the Instructions for Use and the content of the Risk Management File. This blog highlights some of those challenges.

Clinical Evaluation

The Clinical Evaluation Plan (CEP) and Clinical Evaluation Report (CER) are required under MDR to systematically collect, assess, and analyze clinical data throughout the device’s lifecycle.

The CEP outlines a systematic approach for generating and assessing clinical data to demonstrate the device’s safety, performance, and clinical benefits. The CEP includes a description of the device’s intended purpose, intended target population (with any indications or contraindications), the device’s expected clinical benefits, identification of the relevant GSPRs that require clinical data support, the specific methods for examining qualitative and quantitative aspects of clinical safety (including how residual risks and side-effects will be evaluated), and predefined acceptance criteria for determining an acceptable benefit-risk ratio based on the state of the art in medicine.

The CER then documents the conduct and results of the clinical evaluation; it compiles the relevant clinical data, appraises the quality and relevance of those data, and analyzes all relevant data (favorable and unfavorable) to draw conclusions about the device’s safety, clinical performance, and benefits.

A common pitfall is failing to clearly define the device’s intended clinical benefit in the CEP and connect it to specific, measurable, patient-relevant outcomes. Without this clarity at the planning stage, the clinical evaluation may not collect the right data and the CER could fall short of conclusively demonstrating the device’s safety, clinical performance, and benefit-risk profile.

Finally, the clinical evaluation must address all intended indications. There should be sufficient clinical evidence to support each intended use (for example, each relevant anatomical application or disease severity in the target population) and to substantiate any specific claims. Ensuring that every indication and claim are backed by adequate clinical data is essential for MDR compliance and any gaps should be managed via additional data collection or investigations.

Summary of safety and clinical performance

Manufacturers of implantable and Class III devices (excluding custom-made or investigational) must prepare a Summary of Safety and Clinical Performance (SSCP). The SSCP is a public document that provides clear, up-to-date information about the device’s safety and clinical performance to the healthcare professional (intended user) and, where applicable, to patients in an understandable form. The SSCP must comprehensively cover the device’s identification and intended purpose (including indications, contraindications, and target patient groups), possible alternatives, references to any applied harmonized standards or Common Specifications, a summary of the clinical evaluation, any suggested user training or qualifications, and a thorough description of the device’s risks (covering residual risks, known undesirable side-effects, warnings, or precautions). The SSCP must be validated by a Notified Body as part of conformity assessment; once approved, the Notified Body uploads the SSCP to the European database on medical devices (EUDAMED) to make it publicly available. The manufacturer is responsible for keeping the SSCP up to date; it should be reviewed at least annually (in line with the PSUR schedule for such high-risk devices) and revised whenever significant new information arises that could affect the device’s benefit-risk profile. One practical challenge is ensuring that the SSCP patient-oriented content remains both accessible and regularly updated as new significant information that could impact the benefit/risk profile becomes available.

Post-Market Data

The post-market surveillance (PMS plan) outlines methods and procedures for actively gathering, recording, and analyzing relevant post-market data on device quality, performance, and safety throughout its lifecycle. Data sources should include not only sales information, incidents, user feedback, and complaints, but also serious incidents, Field Safety Corrective Actions, user feedback from distributors and importers, registry or literature data, and publicly available information on similar devices. The PMS plan should incorporate trend analysis (manufacturers are required to monitor and report any significant increase in incident frequency or severity that could affect the benefit-risk profile).

For Class I devices, the PMS findings are documented in a Post-Market Surveillance Report (PMS report), which is updated as necessary and made available to regulators upon request. For Class IIa, IIb, and III devices, a Periodic Safety Update Report (PSUR) is required, summarizing the results and conclusions of PMS data (including PMCF findings) along with benefit-risk evaluation. PSURs must be updated at least every two years for Class IIa devices and at least annually for Class IIb and III devices. PSURs for Class III and implantable devices are reviewed by the Notified Body (via Eudamed submission), whereas PSURs for Class IIa/IIb devices should be made available to the Notified Body and competent authorities on request. This class-specific approach ensures that higher-risk devices undergo more frequent, transparent, and detailed post-market scrutiny.

Post-market clinical follow-up (PMCF) is an integral part of PMS and the ongoing clinical evaluation of the device. Every device should have a documented PMCF plan describing the specific methods and procedures to gather clinical data post-market. If a PMCF study or activity is not deemed necessary for a device, the manufacturer must provide a scientifically justified rationale  in the PMCF plan and clinical evaluation explaining why PMCF is not required. Common Notified Body audit findings related to PMCF include an insufficient rationale for not conducting PMCF, lack of PMCF plans targeting specific high-risk populations or worst case device use scenarios, and PMCF data that are not aligned with clinically relevant endpoints or safety/performance outcomes. All PMCF findings must be documented in a PMCF Evaluation Report and be used to update the device’s CER. These findings should also be summarized in the periodic PMS reports (PMS Report or PSUR, as applicable).

Conclusion

The key to avoiding these common MDR clinical evaluation technical documentation pitfalls lies in thoughtful planning. Each device is unique and bears its own challenges. Partnering with a CRO offers the advantage of an objective, external perspective.

Need support planning or documenting your medical device EU MDR clinical evaluation? MED offers a variety of scientific communication services and is a full-service CRO. Contact us today to start your project discussion!

855.463.1633 | askmed@medinstitute.com | medinstitute.com